Could therapeutic drug monitoring of anti-TNF-α be useful to consider a de-escalation of treatment?

Expert Opinion on Biological Therapy

Volumn 15, Issue 11, 2015, Pages 1653-1655

  Flamant, Mathurin ^a   Roblin, Xavier ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

anti TNF; de escalation; inflammatory bowel disease; trough levels

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR; AZATHIOPRINE; IMMUNOLOGIC FACTOR; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INFLAMMATORY BOWEL DISEASE; REMISSION; REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; RECURRENT DISEASE;

AZATHIOPRINE; DRUG MONITORING; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84946042796     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1069273     Document Type: Review

References (7)

1. Felice C, Marzo M, Pugliese D, et al. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opin Biol Ther 2015;7:1-11
2. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70
3. Papamichael K, Vande Casteele N, Gils A, et al. Long-term outcome of patients with crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol 2015;13:1103-10
4. Ben Horin S, Chowers Y, Ungar B, et al. Undetectable anti-TNF drug levels in patients with long term remission successful drug withdrawal. Aliment pharmacol Ther 2015. [Epub ahead of print]
5. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-9
6. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8
7. Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. Clin Gastroenterol Hepatol 2015;13:514-21